Natera (ISIN US6323071042) received FDA Breakthrough Device designation for its multi-cancer early detection assay on October ...

Natera (NASDAQ:NTRA) has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its investigational multi-cancer early detection (MCED) blood test, marking a ...

The FDA has granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A, also known as ABBV-400), an ...

Remaining milestones: The company expects to submit two additional modules, including the final module containing clinical trial data, towards the end of the second quarter in 2027.

Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors. NANJING, China, ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer ...

U.S. FDA (Office of Orphan Products Development) grants Orphan Drug Designation for Sovateltide, a potential first-in-class therapy that could ...

The FDA has granted fast track designation to VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted PRO-XTEN® ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to IKT-001 for treating patients with pulmonary arterial hypertension, ...

VTv Therapeutics said the Food and Drug Administration granted orphan drug designation to HPPD, which is being investigated as a treatment for sickle cell disease.

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with ...